by MM360 Staff | Jan 29, 2026 | Publications
J Geriatr Oncol. 2026 Jan 26;17(2):102846. doi: 10.1016/j.jgo.2025.102846. Online ahead of print. ABSTRACT INTRODUCTION: Improvements in supportive care strategies and growing evidence for benefit have led to increased use of autologous stem cell transplant (ASCT) in...
by MM360 Staff | Jan 29, 2026 | Publications
Pharmaceuticals (Basel). 2025 Dec 21;19(1):18. doi: 10.3390/ph19010018. ABSTRACT Background: Although anti-CD38 monoclonal antibody-based regimens are standard care for newly diagnosed multiple myeloma (NDMM), direct comparative efficacy and comprehensive real-world...
by MM360 Staff | Jan 29, 2026 | Publications
Front Immunol. 2026 Jan 12;16:1722579. doi: 10.3389/fimmu.2025.1722579. eCollection 2025. ABSTRACT Bispecific antibodies are a novel class of immunotherapies that have demonstrated high response rates in heavily pretreated patients with multiple myeloma. However,...
by Marisa Wexler, MS | Jan 28, 2026 | Myeloma News
Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian cancer. That’s according to new data announced by relacorilant’s developer Corcept...
by MM360 Staff | Jan 28, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
